- KSQ-4279 is a first-in-class, potent, and selective small-molecule inhibitor of USP1, a protein that regulates DNA damage response (DDR).
- In July 2023, we entered into a worldwide license and collaboration agreement with Roche for the development and commercialization of KSQ-4279 (RO7623066/RG6614).
- KSQ-4279 (RO7623066/RG6614) was studied in a Phase 1 clinical trial in patients with a variety of advanced solid tumors (NCT05240898)
- KSQ is currently exploring additional applications of KSQ-4279 in other indications.